As GSK seeks next growth driver, daprodustat is not likely the one 

Although GSK’s daprodustat managed to gain backing from an FDA advisory panel in one of two CKD populations, it’s unlikely the therapy would be able to contribute meaningful top-line growth for the pharma.

The mixed advisory committee results were followed by news on Thursday that GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) would not be advancing its late-stage RA therapy otilimab...